fda update on tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA Approves Tirzepatide for Obstructive

For those unfamiliar with my work on obesity, heres the context necessary to understand this issue, and how it relates to the GLP-1 drugs

These bites offer that familiar flavor of melty mozzarella and warm marinara in just a few spoonfuls

Market Will Fragment Before It Consolidates Expect: Confusion at prescription level Rapid brand switching High noise, low clarity But within 1218 months, only a few strong players will dominate

Heres what a few days on the carnivore diet might look like

This is the latest disappointment in what has been a bumpy ride in Pfizer's attempt to enter the hot obesity market and compete with market leaders Eli Lilly (LLY) and Novo Nordisk (NVO)

Most people starting compounded semaglutide notice appetite changes within the first week, but noticeable weight loss on the scale typically emerges after 34 weeks of treatment